Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions

ABSTRACT

Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.

RELATED INVENTIONS

This application is a continuation application of U.S. patentapplication Ser. No. 11/236,059, filed Sep. 26, 2005, now U.S. Pat. No.7,431,932, which is a continuation application of U.S. patentapplication Ser. No. 09/847,356, filed on May 3, 2001, which claims thebenefit of U.S. Provisional Application Ser. No. 60/201,990, filed May3, 2000, Ser. No. 60/205,389, filed May 19, 2000 and Ser. No.60/268,054, filed Feb. 13, 2001, under 35 U.S.C. 119(e). The entiredisclosure of each of the above provisional applications is herebyincorporated by reference.

FIELD OF THE INVENTION

The present invention relates to a method for removing ras-mediatedneoplastic cells from mixed cellular compositions by infecting the mixedcellular compositions with reovirus which selectively lyse theras-mediated neoplastic cells in the compositions.

REFERENCES

-   U.S. Pat. No. 6,136,307.-   Armstrong, G. D. et al., “Studies on reovirus receptors of L cells:    virus binding characteristics and comparison with reovirus receptors    of erythrocytes”, Virology 138:37: 37-48 (1984).-   Bensinger, W. I., “Should we purge?”, Bone Marrow Tranplant. 21:    113-115 (1998).-   Bos, J. L., “Ras Oncogenes in Human Cancer: A Review”, Canc. Res.    49(17): 4682-4689 (1989).-   Chandron and Nibert, “Protease cleavage of reovirus capsid protein    mu1 and mu1C is blocked by alkyl sulfate detergents, yielding a new    type of infectious subvirion particle”, J. of Virology 72(1):467-75    (1998).-   Coffey, M. C., et al., “Reovirus therapy of tumors with activated    Ras pathway”, Science 282: 1332-1334 (1998).-   Duggan, P. R., et al., “Predictive factors for long-term engraftment    of autologous blood stem cells”, Bone Marrow Transplantation 26(12):    1299-1304 (2000).-   Fields, B. N. et al., Fundamental Virology. 3rd Edition,    Lippincott-Raven (1996).-   Gao, J., B. Tombal and J. T. Isaacs, “Rapid in situ hybridization    technique for detecting malignant mouse cell contamination in human    xenograft tissue from nude mice and in vitro cultures from such    xenografts”, Prostate 39(1): 67-70, 1999.-   Gentsch, J. R. K. and Pacitti, A. F., “Effect of neuraminidase    treatment of cells and effect of soluable glycoproteins of type 3    reovirus attachment to murine L cells”, J. Virol. 56:356: 356-64    (1985).-   Neito, Y. and E. J. Shpall, “Autologous stem-cell transplantation    for solid tumors in adults”, Hematol. Oncol. Clin. North Am. 13(5):    939-968 (1999).-   Norman, K. and P. Lee, “Reovirus as a novel oncolytic agent”, J.    Clin. Invest. 105 (8): 1035-1038 (2000).-   Paul R. W. et al., “The alpha-anameric form of sialic acid is the    minimal receptor determinant recognized by reovirus”, Virology 172:    382-385 (1989).-   Sabin, A. B., Science 130: 966 (1959).-   Spyridonidis, A. et al., “Minimal residual disease in autologous    hematopoietic harvests from breast cancer patients”, Annals of    Oncology 9: 821-826 (1998).-   Stewart, D. A., et al., “Superior autologous blood stem cell    mobilization from dose-intensive cyclophosphamide, etoposide,    cisplatin plus G-CSF than from less intensive chemotherapy    regimens”, Bone Marrow Transplant. 23(2): 111-117 (1999).-   Strong, J. E., et al., “The molecular basis of viral oncolysis:    usurpation of the Ras signaling pathway by reovirus”, EMBO J. 17:    3351-3362 (1998).-   Strong, J. E. and P. W. Lee, “The v-erbV oncogene confers enhanced    cellular susceptibility to reovirus infection”, J. Virol. 70:    612-616 (1996).-   Strong, J. E., et al., “Evidence that the Epidermal Growth Factor    Receptor on Host Cells Confers Reovirus Infection Efficiency”,    Virology 197(1): 405-411 (1993).-   Winter, J. N., “High-dose therapy with stem-cell transplantation in    the malignant lymphomas”, Oncology (Huntingt). 13(12): 1635-1645    (1999).-   WO 99/08692, published Feb. 25, 1999.

All of the above publications, patents and patent applications areherein incorporated by reference in their entirety to the same extent asif the disclosure of each individual publication, patent application orpatent was specifically and individually indicated to be incorporated byreference in its entirety.

BACKGROUND OF THE INVENTION

Normally, cell proliferation is regulated by both growth-promotingsignals and growth-constraining signals. These two kinds of signals foreach cell would normally strike a balance in a manner which reflects theneed of the body for the particular cell. If a cell fails to respond tothe growth-constraining signals or over-responds to the growth-promotingsignals, it will proliferate abnormally fast (referred to as neoplasticcells) and may eventually develop into cancer, a malignant neoplasm.

Chemotherapy, a current method of treating cancer, is generally based onthe fast-proliferating property of cancer cells. Since cancer cellsproliferate rapidly, they are more sensitive to drugs which inhibitcellular proliferation. In theory, by carefully choosing the dosage ofchemotherapeutic drugs, one can inhibit cancer cell proliferationwithout seriously damaging normal cells. However, some normal cells,such as hematopoietic stem cells, also proliferate rapidly. Therefore,any dosage which is harmful to cancer cells is often also harmful to thehematopoietic stem cells. On the other hand, if the dosage is not highenough to kill the cancer cells, there is the risk that the cancer wouldreappear shortly after chemotherapy is terminated.

Because it is hard to find a dosage which selectively kills cancercells, high-dose chemotherapy followed by autologous hematopoieticprogenitor stem cell transplantation has gained extensive application asa therapeutic approach in many cancers (see, for example, Winter, 1999;Nieto and Shpall, 1999). In this approach, a portion of thehematopoietic stem cells is removed from a cancer patient, and thepatient is then treated with high-dose chemotherapy which is lethal torapid-proliferating cells, such as cancer cells and hematopoietic stemcells. Subsequently, the patient receives transplantation of autologoushematopoietic stem cells which have been previously removed from thesame patient to regenerate the hematopoietic system.

A serious drawback of this therapy is that when the hematopoieticprogenitor stem cells are removed from the patients, they are oftencontaminated with cancer cells. This is especially a problem when thepatient has a cancer of the hematopoietic origin, but patients with asolid tumor may also suffer from contamination of the hematopoietic stemcells, particularly if the solid tumor has metastasized. As a result,when the removed cells are transplanted back to reestablish thehematopoietic system, some cancer cells may also be placed back to thecancer patient where they may proliferate again and contribute to cancerrecurrence. It is therefore desirable to purge the autografts beforetransplantation.

Several methods have been employed to purge autographs (Spyridonidis etal, 1998; Bensinger 1998). The autograph can be treated withchemotherapy to kill the contaminating neoplastic cells in vitro.However, as discussed above, it is hard to find a dosage for thechemotherapeutic drug which selectively kills neoplastic cells or cancercells but leaves normal hematopoietic stem cells intact. Autographs canalso be treated with a toxin conjugated to antibodies which recognize anantigen that is specific to the neoplastic cells, but such a tumorspecific antigen does not always exist.

It is also possible to separate stem cells from the other cells based ona stem cell specific surface marker (CD34) by using flow cytometry,affinity columns or magnetic beads. However, by selecting only certainhematopoietic cells, e.g., the CD34⁺ cells, other hematopoietic cellssuch as T cells, B cells, monocytes and natural killer cells are alsoeliminated, and immune recovery may be delayed (Bensinger, 1998). Thismethod also results in the loss of about half the CD34⁺ cells andretention of some contaminating cancer cells (Spyridonidis et al.,1998). Therefore, there remains a need for a highly selective methodwith a reasonable yield to purge autografts which may contain neoplasticcells.

SUMMARY OF THE INVENTION

The present invention is directed to a method for removing ras-mediatedneoplastic cells from mixed cellular compositions by infecting the mixedcellular compositions with reovirus which selectively lyses ras-mediatedneoplastic cells. Since many neoplastic cells are associated with anactivated ras pathway, the present invention can be used to remove thecontaminating or spontaneous neoplastic cells from a wide variety ofmixed cellular compositions.

Accordingly, one aspect of the present invention provides a method toremove ras-mediated neoplastic cells from a cellular compositionsuspected of containing such neoplastic cells, which method comprisescontacting the cellular composition with reovirus under conditions whichresult in oncolysis of the ras-mediated neoplastic cells.

In a preferred embodiment of the present invention, a cellularcomposition comprising hematopoietic stem cells is treated to removeras-mediated neoplastic cells which exist in the cellular composition ascontaminating or spontaneously occurring neoplastic cells. Sincereovirus is highly selective and lytically infects ras-mediated cellsonly, this method does not affect the ability of hematopoietic stemcells to differentiate and reconstitute the hematopoietic system. Themethod can be used to purge hematopoietic stem cells from bone marrow orblood. The hematopoietic stem cells may be autologous, allogeneic orxenogeneic.

In another embodiment of the invention, reovirus is used to removeras-mediated neoplastic cells from a tissue or organ transplant prior totransplantation. Because this method can be applied without regard tothe type or age of the transplant or of the ras-mediated cell, andbecause the reovirus is essentially harmless to normal cells andtissues, this method can be used as a routine practice to “clean up” anytransplant before transplantation.

In another embodiment of the invention, reovirus can be used to treatcultured cell lines to remove cells which are spontaneously transformeddue to activation of the ras pathway. This method can also be used totreat semen or donor eggs before artificial insemination or otherreproduction-related procedures.

The reovirus useful in this invention may be any reovirus. Preferablythe reovirus is a mammalian reovirus, more preferably a human reovirus.Still more preferably the reovirus is a serotype 3 reovirus, mostpreferably the Dearing Strain reovirus.

In another embodiment of the invention, the method further comprises thestep of freezing and storing the reovirus-treated cellular compositionin a solution containing DMSO. DMSO is routinely used to freeze andstore animal cells but it denatures the reovirus. Therefore thistreatment removes infectious reovirus from the cellular compositionwhile preserving the activity of the composition in the frozen state fora prolonged period of time.

In another embodiment of the present invention, reovirus is removed fromthe reovirus-treated cellular composition by subjecting the mixture toanti-reovirus antibodies or a combination of anti-reovirus antibodiesand complement in order to lyse the reovirus. Alternatively oradditionally, anti-reovirus antibodies which recognize a molecule on thesurface of the reovirus particle may be used to remove the reovirusparticles by immobilizing the antibodies, applying the cellularcomposition to the immobilized antibodies, and collecting the part ofthe composition which does not bind to the antibodies.

Similarly, anti-reovirus antibodies can be administered to thetransplant recipient to eliminate reovirus in vivo, or the recipient canbe given an immune system stimulant to achieve this purpose.

In another embodiment of the present invention, reovirus is removed fromthe reovirus-treated cellular composition by using a gradient which canseparate reovirus from cells.

Also provided are cellular compositions which have been treated withreovirus to remove ras-mediated neoplastic cells. Such compositions maybe used for in vitro research, or in transplantation, insemination, orother in vivo procedures. The transplantation may be autologous,allogeneic, or even xenogeneic. Preferably the transplantation isautologous. More preferably, the composition comprises hematopoieticstem cells.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1

FIGS. 1A-1C show the number of viable cells in MCF7 (FIG. 1A), SKBR3(FIG. 1B) or MDA MB 468 (ATCC No. HTB132; FIG. 1C) which were infectedwith live reovirus, dead virus or no virus as indicated. FIG. 1D showsthe percentage of MCF7 cells which were viable at various time pointsafter reovirus infection.

FIG. 2

FIG. 2 shows that apoptosis was induced by reovirus infection in MCF7,SKBR3 or MDA MB 468 cells. FIGS. 2A-2C demonstrate the percentage DNAwhich were fragmented after reovirus infection. FIG. 2D shows thepercentage of the apoptotic marker Annexin V staining after reovirusinfection. FIGS. 2E-2G show the percentage of APO2.7⁺ cells in each celltype as indicated.

FIG. 3

FIG. 3A shows the number of viable cells at various time points afterCD34⁺ stem cells had been infected with reovirus. FIG. 3B shows theeffect of reovirus on long-term stem cell culture. Stem cells wereinfected with reovirus and incubated for 2, 24, 48 or 72 hours,respectively, then the cells were diluted and cultured for 14 days toallow individual colonies to form. The number of each kind of colony,granulocytes (G), erythroids (E) or granulocyte erythroid macrophagemegakaryocyte (GEMM), was then determined for cells infected with novirus (NV) or live virus (LV), respectively. For example, NV-G standsfor the granulocyte colonies derived from cells which were treated withno virus, and LV-G stands for those derived from cells which weretreated with live reovirus.

FIG. 4

FIGS. 4A-4C show the purging effects of reovirus on mixtures ofapheresis product with MCF7, MDA MB 468 or SKBR3 cells, respectively.

DETAILED DESCRIPTION OF THE INVENTION

The invention is directed to methods of removing ras-mediated neoplasticcells from a cellular composition by using reovirus, and to compositionswhich have been treated according to these methods.

Prior to describing the invention in further detail, the terms used inthis description are defined as follows unless otherwise indicated.

DEFINITIONS

As used herein, “neoplastic cells”, also known as “cells with aproliferative disorder”, refer to cells which proliferate without thenormal growth inhibition properties. A new growth comprising neoplasticcells is a neoplasm or tumor. A neoplasm is an abnormal tissue growth,generally forming a distinct mass, that grows by cellular proliferationmore rapidly than normal tissue growth. Neoplasms may show partial ortotal lack of structural organization and functional coordination withnormal tissue. As used herein, a neoplasm is intended to encompasshematopoietic neoplasms as well as solid neoplasms.

A neoplasm may be benign (benign tumor) or malignant (malignant tumor orcancer). Malignant tumors can be broadly classified into three majortypes. Malignant neoplasms arising from epithelial structures are calledcarcinomas, malignant neoplasms that originate from connective tissuessuch as muscle, cartilage, fat or bone are called sarcomas and malignanttumors affecting hematopoietic structures (structures pertaining to theformation of blood cells) including components of the immune system, arecalled leukemias and lymphomas. Other neoplasms include, but are notlimited to neurofibromatosis.

As used herein, “ras-activated neoplastic cells” or “ras-mediatedneoplastic cells” refer to cells which proliferate at an abnormally highrate due to, at least in part, activation of the ras pathway. The raspathway may be activated by way of ras gene structural mutation,elevated level of ras gene expression, elevated stability of the rasgene message, or any mutation or other mechanism which leads to theactivation of ras or a factor or factors downstream or upstream from rasin the ras pathway, thereby increasing the ras pathway activity. Forexample, activation of EGF receptor, PDGF receptor or Sos results inactivation of the ras pathway. Ras-mediated neoplastic cells include,but are not limited to, ras-mediated cancer cells, which are cellsproliferating in a malignant manner due to activation of the raspathway.

As used herein, “cellular composition” means a composition comprisingcells. The composition may contain non-cellular matter. For example,whole blood is a cellular composition which contains plasma, platelets,hormones and other non-cellular matter in addition to cells such aserythrocytes and leukocytes. A cellular composition may contain cells ofvarious types, origin or organization. For example, tissues and organswhich contain different cell types arranged in defined structures areconsidered cellular compositions.

As used herein, “reovirus” refers to any virus classified in thereovirus genus. The name reovirus (Respiratory and enteric orphan virus)is a descriptive acronym suggesting that these viruses, although notassociated with any known disease state in humans, can be isolated fromboth the respiratory and enteric tracts (Sabin, 1959). The term“reovirus” refers to all viruses classified in the reovirus genus.

The human reovirus consists of three serotypes: type 1 (strain Lang orT1L), type 2 (strain Jones, T2J) and type 3 (strain Dearing or strainAbney, T3D). The three serotypes are easily identifiable on the basis ofneutralization and hemagglutinin-inhibition assays (See, for example,Fields et al., 1996).

The reovirus may be naturally occurring or modified. The reovirus is“naturally-occurring” when it can be isolated from a source in natureand has not been intentionally modified by humans in the laboratory. Forexample, the reovirus can be from a “field source”, that is, from ahuman who has been infected with the reovirus.

The reovirus may be modified but still capable of lytically infecting amammalian cell having an active ras pathway. The reovirus may bechemically or biochemically pretreated (e.g., by treatment with aprotease, such as chymotrypsin or trypsin) prior to administration tothe proliferating cells. Pretreatment with a protease removes the outercoat or capsid of the virus and may increase the infectivity of thevirus. The reovirus may be coated in a liposome or micelle (Chandron andNibert, 1998) to reduce or prevent an immune response from a mammalwhich has developed immunity to the reovirus. For example, the virionmay be treated with chymotrypsin in the presence of micelle formingconcentrations of alkyl sulfate detergents to generate a new infectioussubvirion particle.

The reovirus may be a recombinant reovirus from two or more types ofreoviruses with differing pathogenic phenotypes such that it containsdifferent antigenic determinants, thereby reducing or preventing animmune response by a mammal previously exposed to a reovirus subtype.Such recombinant virions can be generated by co-infection of mammaliancells with different subtypes of reovirus with the resulting resortingand incorporation of different subtype coat proteins into the resultingvirion capsids.

“Resistance” of cells to reovirus infection indicates that infection ofthe cells with the virus did not result in significant viral productionor yield. Cells that are “susceptible” are those that demonstrateinduction of cytopathic effects, viral protein synthesis, and/or virusproduction. Resistance to reovirus infection was found to be at thelevel of gene translation, rather than at early transcription: whileviral transcripts were produced, virus proteins were not expressed.Without being limited to a theory, it is thought that viral genetranscription in resistant cells correlated with phosphorylation of anapproximately 65 kDa cell protein, determined to be double-strandedRNA-activated protein kinase (PKR); that was not observed in transformedcells. Phosphorylation of PKR lead to inhibition of translation. Whenphosphorylation was suppressed by 2-aminopurine, a known inhibitor ofPKR, drastic enhancement of reovirus protein synthesis occurred in theuntransformed cells.

As used herein, “oncolysis” or “decrease of viability of neoplasticcells” refers to a decrease of at least about 20% in viability of thetarget neoplastic cells. The viability can be determined by a viablecell count of the treated cells, and the extent of decrease can bedetermined by comparing the number of viable cells in the treated cellsto that in the untreated cells, or by comparing the viable cell countbefore and after reovirus treatment. The decrease in viability ispreferably at least about 50%, more preferably at least about 70%, stillmore preferably at least about 80%, and most preferably at least about90%.

As used herein, a “transplant recipient” is a mammal which receives atransplantation of cellular compositions. Preferably the recipient is ahuman, and more preferably a recipient is a human who is receivingtransplantation in the treatment of cancer.

As used herein, “CPE” as an apoptotic marker refers to the cytopathiceffects typically associated with apoptosis which are observable underthe microscope, such as cell membrane blebbing, nuclear condensation andchromatin condensation.

Methods

The present invention relates to the use of reovirus to removeras-mediated neoplastic cells from cellular compositions which aresuspected of containing such neoplastic cells. Since the activated raspathway is associated with many tumors, this invention can be applied tocellular compositions suspected of having any of a large variety ofneoplastic cells.

For mammalian reoviruses, the cell surface recognition signal is sialicacid (Armstrong, 1984; Gentsch and Pacirti, 1985; Paul et al., 1989).Due to the ubiquitous nature of sialic acid, reovirus binds efficientlyto a multitude of cell lines and as such can potentially target manydifferent tissues; however, there are significant differences insusceptibility to reovirus infection between cell lines. One reason forthis discrepancy in susceptibility may be the activity of the raspathway in each cell type.

We recently discovered that reovirus selectively lyses ras activatedneoplastic cells in vitro, in vivo and ex vivo (Coffey et al., 1998; WO99/08692). Normally, cells are not susceptible to reovirus infection.However, when the ras pathway is activated, reovirus can successfullyreplicate in the cells and eventually results in lysis of the hostcells. For example, when reovirus-resistant NIH 3T3 cells weretransformed with activated Ras or Sos, a protein which activates Ras,reovirus infection was enhanced (Strong et al., 1998). Similarly, mousefibroblasts that are resistant to reovirus infection became susceptibleafter transfection with the EGF receptor gene or the v-erbB oncogene(Strong et al., 1993; Strong et al., 1996).

Without being limited to a theory, it seems that reovirus replication isregulated at the translational level (Strong et al., 1998; Norman etal., 2000). In untransformed NIH 3T3 cells, early viral transcriptsactivate the double-stranded RNA-activated protein kinase (PKR), whichinhibits translation, thereby inhibiting viral replication. ActivatedRas (or an activated element of the ras pathway) presumably inhibits orreverses PKR activation. Therefore, viral protein synthesis proceeds,viral particles are made, and the cells are eventually lysed.

The ras oncogene accounts for a large number of tumors. Activatingmutations of the ras gene itself occur in about 30% of all human tumors(Bos, J. L., 1989), primarily in pancreatic (90%), sporadic colorectal(50%) and lung (40%) carcinomas, and myeloid leukemia (30%). Activationof the factors upstream or downstream of ras in the ras pathway is alsoassociated with tumors. For example, overexpression of HER2/Neu/ErbB2 orthe epidermal growth factor (EGF) receptor is common in breast cancer(25-30%), and overexpression of platelet-derived growth factor (PDGF)receptor or EGF receptor is prevalent in gliomas and glioblastomas(40-50%). EGF receptor and PDGF receptor are both known to activate rasupon binding to their respective ligand, and v-erbB encodes aconstitutively activated receptor lacking the extracellular domain.

We demonstrate in this invention that reovirus efficiently causedoncolysis of three breast cancer model systems, MCF7, SKBR3 and MDA MB468, by inducing apoptosis in the infected cells (Example 1). Thus,reovirus treatment resulted in a marked decrease in viability of MCF7,SKBR3 and MDA MB 468 cells, while controls treated with no virus or deadvirus grew normally (FIGS. 1A-1D). The decrease in viability wasaccompanied by characteristics which are associated with apoptosis, suchas DNA fragmentation, annexin V or APO 2.7 staining positivity (FIGS.2A-2G) and cytopathic effects, such as cell membrane blebbing, nuclearcondensation and chromatin condensation observed under the microscope.

Since reovirus infection is usually blocked at the translational levelin normal cells but not in ras-mediated neoplastic cells, we examinedthe extent of protein synthesis in reovirus treated MCF7 cells and CD34⁺stem cells (Example 2). Indeed, viral proteins were synthesized in thereovirus infected cancer cell line, but not in CD34⁺ stem cells whichwere also treated with reovirus (data not shown). This result suggeststhat it will be safe to treat hematopoietic stem cells with reovirus,since reoviral proteins were not synthesized in reovirus treated stemcells and cellular protein synthesis proceeded normally. To confirm thispoint, viability of the reovirus treated CD34⁺ cells was determined atvarious time points after reovirus treatment (Example 3). Cell numbersin populations treated with live reovirus or no virus were similar aftereach time point (FIG. 3A), indicating that CD34⁺ cells are notsusceptible to reovirus infection.

In order for reovirus to be useful in purging hematopoietic stem cell inhigh dose chemotherapy treatments, it is essential that the reovirustreatment does not alter the ability of stem cells to differentiate intoeach and every hematopoietic lineage to reconstitute the wholehematopoietic system. Therefore, long term effect of reovirus treatmentwas assessed (Example 3). CD34⁺ cells treated with either no virus orlive virus showed essentially no difference in their ability todifferentiate into granulocytes, erythroids, or granulocyte erythroidmacrophage megakaryocytes even after 72 hours of reovirus treatment(FIG. 3B). The ratio between these three lineages also remained the sameafter this prolonged treatment. Accordingly, reovirus treatment neitherkilled CD34⁺ cells nor changed the potential of them to reconstitute thehematopoietic system.

Furthermore, reovirus is capable of purging a mixed cellularcomposition, as demonstrated by the selective killing of MCF7, SKBR3 orMDA MB 468 cells in a mixture of cancer cells and apheresis productwhich contained CD34⁺ stem cells (Example 4). By measuring CD34 andcytokeratin, a marker specific for epithelial cells such as MCF7, SKBR3or MDA MB 468, it was shown that reovirus essentially eliminated thecancer cells from the mixed cellular composition (FIGS. 4A-4C) whileleaving the stem cells intact. Therefore, reovirus treatment is anefficient method to purge neoplastic cells from hematopoietic stem cellcompositions.

Accordingly, in the preferred embodiment of this invention, stemcell-containing autographs are treated with reovirus prior totransplantation to remove the contaminating or spontaneous ras-mediatedneoplastic cells. This increases the efficacy of the high dosechemotherapy/autologous hematopoietic stem cell transplantationtreatment. Of particular interest will be the treatment of Hodgkin'sdisease, multiple myeloma, non-Hodgkin's lymphoma, acute myelogenousleukemia, germ cell (testicular) cancers, brain tumors, and breasttumors, since high dose chemotherapy and autologous stem celltransplantation have been performed efficiently in patients with thesetumors. However, it is contemplated that the present method will beuseful in other cancers as well to remove any ras-mediated neoplasticcells, since activation of the ras pathway may occur in any cell ortissue type.

Hematopoietic progenitor stem cells can be removed from bone marrow ofthe patient in advance of treatment. Alternatively, in a cancer patientwho has been receiving traditional, non-high dose chemotherapy, manystem cells typically appear in the peripheral blood. Therefore,hematopoietic progenitor stem cell can be removed from the blood asapheresis product, which can be stored for a long time before beingtransplanted. The present invention can be applied to stemcell-containing autographs which are harvested from any tissue source,including bone marrow and blood.

Although reovirus normally is not associated with any known disease, itmay be more infectious to cancer patients whose immune systems areweakened due to chemotherapy. Accordingly, in another embodiment of thisinvention, the stem cell compositions which have been treated withreovirus are frozen in a solution containing DMSO and thawed prior totransplantation. While DMSO is routinely used to freeze and store animalcells, it denatures reovirus, thereby removing infectious reovirus fromthe stem cell preparation. This reduces the risk that reovirus may causeundesired infections when it is introduced into the transplant recipientvia stem cell transplantation.

In another embodiment, the reovirus-treated cell compositions aretreated with anti-reovirus antibodies or a combination of anti-reovirusantibodies and complements in order to inactivate or lyse the reovirus.Alternatively or additionally, anti-reovirus antibodies which recognizea molecule on the surface of the reovirus particle may be used to removethe reovirus particles from the reovirus-treated cellular composition.Thus, the antibodies are immobilized to a column, beads or any othermaterial or device known in the art, the cellular composition is appliedto the immobilized antibodies, and the part of the composition whichdoes not bind to the antibodies is collected according to a proceduresuitable for the particular method of immobilization.

Another method which may be used to remove reovirus from thereovirus-treated mixture is to subject the mixture to a gradient whichseparates cells from the virus, and collect the layer that contains onlythe cells.

In another embodiment, the transplant recipient is given treatments tostimulate the immune system in order to reduce the risk of reovirusinfection. This treatment may be performed prior to, contemporaneouslywith, or after the transplantation, but is preferably performed prior tothe transplantation. As an alternative treatment or in conjunction withthe immune system stimulant, the recipient can be given anti-reovirusantibodies in order to reduce the risk of reovirus infection.

In addition to hematopoietic stem cells, the present invention can bebroadly applied to remove ras-mediated neoplastic cells from many othercellular compositions. For example, reovirus can be used as a routinepractice to “clean up” (remove ras-mediated neoplastic cells from) anytissue or organ transplant. Application of the present invention is notlimited by cell or tissue type because as discussed above, the receptorfor reovirus is ubiquitous, and the mechanism in normal cells to inhibitreovirus replication, PKR, is also ubiquitous. Therefore, any cell maybecome a ras-mediated neoplastic cell and become susceptible to reovirusinfection. Of particular interest will be the use of the claimed methodsto clean up whole blood or any portion thereof for a subsequenttransfusion. Similarly, tissue or organ transplantation has becomeincreasingly common, and it will be beneficial if the transplant can betreated to remove ras-mediated neoplastic cells before transplantation.Liver, kidney, heart, cornea, skin graft, pancreatic islet cells, bonemarrow or any portions thereof are just a few examples of the tissues ororgans to which this invention can be applied.

The tissue or organ can be autologous, allogeneic or xenogeneic. Thetissue or organ may also be derived from a transgenic animal, be atissue/organ which is developed in vitro from stem cells, or be expandedex vivo. The tissue or organ to be treated with reovirus can be from anembryonic or adult origin. For example, embryonic neuronal cells can betreated before being transplanted into an Alzheimer's patient.Similarly, the invention can be used to treat semen or donor eggs exvivo.

Application of the present invention is not limited to transplants.Rather, any cellular compositions can be “cleaned up” with reovirus forany purpose. Thus, all the examples described above are applicable evenif the tissue or organ is not meant for transplantation.

Cell lines may also be treated routinely to safeguard againstspontaneous or contaminating ras-mediated neoplastic cells. Again, anycell line will be a good candidate for this method except, of course, acell line transformed by means of activation of the ras pathway.

Recently, many laboratories have been attempting to establish seriallytransplantable xenografts of human prostate cancer tissue inoculatedinto immune-compromised mice. However, contamination with mouse cancercells often occurs during the serial passage of the xenografts and thesecalls can eventually outgrow the human prostate cancer cells (Gao etal., 1999). The present invention will be a simple solution to thisproblem if the contaminating cancer is ras-mediated and the xenograft isnot.

The following examples are offered to illustrate this invention and arenot to be construed in any way as limiting the scope of the presentinvention.

EXAMPLES

In the examples below, the following abbreviations have the followingmeanings. Abbreviations not defined have their generally acceptedmeanings.

-   -   μM=micromolar    -   mM=millimolar    -   M=molar    -   ml=milliliter    -   μl=microliter    -   mg=milligram    -   μg=microgram    -   PAGE=polyacrylamide gel electrophoresis    -   rpm=revolutions per minute    -   FBS=fetal bovine serum    -   DTT=dithiothrietol    -   SDS=sodium dodecyl sulfate    -   PBS=phosphate buffered saline    -   DMEM=Dulbecco's modified Eagle's medium    -   α-MEM=α-modified Eagle's medium    -   β-ME=β-mercaptoethanol    -   MOI=multiplicity of infection    -   PFU=plaque forming units    -   PKR=double-stranded RNA activated protein kinase    -   EGF=epidermal growth factor    -   PDGF=platelet derived growth factor    -   DMSO=dimethylsulfoxide    -   CPE=cytopathic effect

Example 1 Reovirus Induced Oncolysis and Apoptosis in Breast CancerCells

To determine the effect of reovirus on the viability of neoplasticcells, we first used three breast cancer model systems, MCF7 (ATCCnumber HTB-22), SKBR3 (ATCC number HTB-30) and MDA MB 468 (ATCC numberHTB 132). Cells of each cell line were grown to 50-60% confluency andinfected with reovirus serotype 3, strain Dearing, at a multiplicity ofinfection of 40. Reovirus was obtained and maintained as described inU.S. Pat. No. 6,136,307. Reovirus infected and non-infected cells wereharvested at 0, 24, 48 and 72 hours after infection and the viabilitywas determined.

The results are shown in FIGS. 1A-1D. Viable cell count inreovirus-infected MCF7 (FIG. 1A), SKBR3 (FIG. 1B) or MDA MB 468 cells(FIG. 1C) dropped significantly after the infection, while the cellsinfected with dead virus or no virus proliferated as expected. Reovirustreatment caused MCF7 (FIG. 1D) and SKBR3 viability to drop from 93% to16% by 72 hours after infection. In MDA MB 468 cells, virus treatedintact cell numbers dropped to 12.7%, 8.8% and 3.6% of the original cellcounts, respectively, at 24, 48 and 72 hours after infection. Thus,reovirus caused oncolysis efficiently in all three kinds of cancercells.

The cells died by apoptosis. Typical apoptotic markers such as CPE,Annexin-V and DNA laddering could be observed in a time course parallelto the decrease of viability. FIGS. 2A-2G show the percentage of DNAfragmentation (2A-2C), Annexin V staining (2D) or APO2.7⁺ cells (2E-2G)at various time points after reovirus infection. The reovirus treatedcells exhibited all signs of apoptosis at a dramatic level compared tothe no virus or dead virus controls, demonstrating that reovirus inducedapoptosis in all of these three cell lines. Apoptosis in the controlsseemed to increase slowly with time as well, probably because cellsbegan to die when they had grown too densely.

Example 2 Reovirus Selectively Inhibited Protein Synthesis in CancerCells but not CD34⁺ Stem Cells

For further proof of selective viral infection of cancer cells, ³⁵Slabeling/SDS/PAGE of viral proteins was undertaken. Viral proteinsynthesis was evident after 1-2 days in MCF7 cells infected withreovirus, while cellular protein synthesis decreased at the same time,indicating that reovirus had taken over the cellular machinery. At 4days after infection, no protein synthesis could be detected anymore,suggesting that all the cells had been killed. In the controlexperiments where cells were infected with dead reovirus or no virus,there was no viral protein synthesis, whereas cellular protein synthesiswas at the normal level. In contrast, ³⁵S labeling of CD34⁺ stem cellsin the presence or absence of reovirus showed no viral protein synthesisup to 72 hours after the addition of virus. Therefore, reovirusselectively infect MCF7 cells but not CD34⁺ stem cells.

Example 3 Reovirus Treatment Neither Inhibited Cell Proliferation NorAltered Differentiation Potential of CD34⁺ Cells

Consistent with the protein synthesis results, viable cell countindicated that reovirus treatment did not decrease the number of viablecells in CD34⁺ cells (FIG. 3A) as compared to the no virus control.

While the number of CD34⁺ cells was unaffected by reovirus infection,there remained the question whether reovirus changed the potential ofCD34⁺ stem cells to differentiate into all the hematopoietic lineages inthe appropriate proportion. If this was the case, reovirus treated stemcells would not be a good candidate for the reconstitution of the wholehematopoietic system. To investigate this possibility, CD34⁺ cells wereincubated with reovirus for 2, 24, 48 or 72 hours, respectively. Thereovirus was then removed and the cells were diluted and cultured infresh media for 14 days to allow colonies to form. Each colony wasexamined to determine if it belongs to the granulocyte, erythroid, orgranulocyte erythroid macrophage megakaryocyte lineage. As shown in FIG.3B, stem cells treated with live virus (LV) yielded similar numbers ofgranulocutes (G), erythrocytes (E) or granulocyte erythroid macrophagemegakaryocytes (GEMM) as the no virus (NV) control. Therefore, reovirustreatment did not change the differentiation potential of CD34⁺ cells.

Example 4 Reovirus Selectively Removed Cancer Cells from a MixedCellular Composition

Neoplastic cells were mixed with apheresis product and subjected toreovirus infection to investigate if reovirus can selectively removeneoplastic cells from the mixed cellular composition. Apheresis productwas prepared according to a procedure previously described (Stewart etal., 1999; Duggan et al., 2000). When admixtures of apheresis product(90%) and MCF7 (10%) were treated with reovirus and tested daily forcell count and viability, there was a 100-fold depletion in the numbersof cytokeratin-positive MCF7 cells while the CD34⁺ stem cells remainedintact and viable (FIG. 4A). Reovirus was similarly effective inselectively removing MDA MB 468 (FIG. 4B) or SKBR3 cells (FIG. 4C) fromtheir mixture with apheresis product, respectively. These resultsdemonstrate that reovirus can selectively kill neoplastic cells in acell mixture and leave the stem cells intact.

1. A method for transplanting a cellular composition into a mammal,comprising the steps of: a) administering a reovirus to the mammal in anamount sufficient to elicit an immune response to the reovirus in themammal, and b) transplanting into the mammal a cellular composition thathas been purged with the reovirus.
 2. The method of claim 1, whereinstep (a) occurs contemporaneously with or after step (b).
 3. The methodof claim 1, wherein step (a) occurs prior to step (b).
 4. The method ofclaim 1, wherein the cellular composition comprises hematopoietic stemcells.
 5. The method of claim 4, wherein the hematopoietic stem cellsare harvested from the blood of the mammal.
 6. The method of claim 4,wherein the hematopoietic stem cells are harvested from the bone marrowof the mammal.
 7. The method of claim 1, wherein the cellularcomposition comprises a tissue, an organ or any portion of a tissue oran organ.
 8. The method of claim 7, wherein the tissue or organ isselected from the group consisting of liver, kidney, heart, cornea,skin, lung, pancreatic islet cells, and whole blood.
 9. The method ofclaim 1, wherein the mammal suffers from a neoplasm.
 10. The method ofclaim 9, wherein the neoplasm is a ras-mediated neoplasm.
 11. The methodof claim 9, wherein the neoplasm is selected from the group consistingof lung cancer, prostate cancer, colorectal cancer, thyroid cancer,renal cancer, adrenal cancer, liver cancer, pancreatic cancer, breastcancer and central and peripheral nervous system cancer.
 12. The methodof claim 9, wherein the neoplasm is selected from the group consistingof Hodgkin's disease, multiple myeloma, non-Hodgkin's lymphoma, acutemyclogenous leukemia, germ cell (testicular) cancers, brain tumors, andbreast tumors.
 13. The method of claim 1, wherein the mammal alsoreceives a chemotherapeutic agent or radiation therapy.
 14. The methodof claim 1, wherein the purged cellular composition is stored in thepresence of DMSO prior to transplantation.
 15. The method of claim 1,wherein the reovirus is selected from the group consisting of serotype 1reovirus, serotype 2 reovirus and serotype 3 reovirus.
 16. The method ofclaim 1, wherein the reovirus is a recombinant reovirus.
 17. The methodof claim 1, wherein the reovirus is a modified reovirus.
 18. The methodof claim 1, further comprising the step of treating the reovirus-treatedcomposition with an anti-reovirus antibody.
 19. The method of claim 1,further comprising subjecting the reovirus-treated cellular compositionto a gradient that separates the cells of the cellular composition fromthe reovirus.
 20. The method of claim 19, further comprising collectingthe layer that contains the cells of the cellular composition.